A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy-Reference-Cited by-同舟云学术

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

Published:2016-11-28 Issue:12 Volume:68 Page:2867-2877
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Kremer Joel M.¹,Emery Paul²,Camp Heidi S.³,Friedman Alan³,Wang Li³,Othman Ahmed A.³,Khan Nasser³,Pangan Aileen L.³,Jungerwirth Steven³,Keystone Edward C.⁴

Affiliation:

1. Albany Medical College; Albany New York

2. University of Leeds and Leeds Teaching Hospitals NHS Trust; Leeds UK

3. AbbVie; North Chicago Illinois

4. Mount Sinai Hospital, University of Toronto; Toronto, Ontario Canada

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Reference33 articles.

1. Emerging therapies for rheumatoid arthritis;Jacques;Expert Opin Emerg Drugs,2013

2. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis;Finckh;Ann Rheum Dis,2006